Brittany Lovely

Although adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer, the agent did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

Liposomal irinotecan (Onivyde) plus 5-fluorouracil/leucovorin (5-FU/LV) mproved progression-free survival (PFS) and overall survival (OS) in patients with metastatic biliary tract cancer whose disease had progressed after frontline gemcitabine/cisplatin.

Results of the phase 2 SPEARHEAD-1 trial were presented at the 2021 ASCO Annual Meeting, with a high overall response rate reported with afamitresgene autoleucel in advanced synovial sarcoma or myxoid/round cell liposarcoma.

A durable clinical benefit was seen from the dual inhibition of the MAPK pathway using BRAF and MEK inhibitors dabrafenib and trametinib, respectively, to treat patients with BRAF V600E mutant low- and high-grade glioma.

In preliminary findings from the ongoing first-in-human KOMET-001 trial, KO-539 showed activity in patients with relapsed or refractory acute myeloid leukemia.

Research presented at the 2020 ASH Annual Meeting may have found an alternative path forward for patients who do not respond to immunotherapy treatment for large B-cell lymphomas.

Apatinib in combination with gefitinib in the first-line setting demonstrated superior progression-free survival (PFS) in patients with advanced EGFR-mutant non–small cell lung cancer.

The first-in-class inhibitor of apoptosis protein (IAP) antagonist significantly improved overall survival in patients with LA-SCCHN.

Induction avelumab prior to standard of care led to a clinically relevant worsening of survival as the first-line treatment for patients with metastatic urothelial carcinoma.

Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated  in patients with heavily pretreated relapsed or refractory multiple myeloma.

Atezolizumab monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment in patients with wild-type non–small cell lung cancer with PD-L1 expression ≥50%.

PRS-343, a HER2/4-1BB targeting bispecific construct, is well-tolerated and demonstrated anti-tumor activity in heavily pre-treated patient population across multiple tumor types.